LENZ Therapeutics (LENZ) announced that the U.S. Food and Drug Administration, FDA, has accepted the Company’s New Drug Application, NDA, ...

LNZ100 is a single-use, once-daily eye drop containing aceclidine, a small molecule acetylcholine receptor agonist that causes miosis.

The NDA submission for the treatment of presbyopia is supported by the positive data results from the pivotal Phase 3 CLARITY study. Aceclidine is a new chemical entity in the United States and is not ...

LENZ Therapeutics said the submission for the treatment of presbyopia is supported by the positive data results from a Phase 3 study. Aceclidine is a new chemical entity in the U.S. and isn't approved ...

today announced presentations featuring LNZ100 at multiple upcoming ophthalmology and optometry medical conferences, including Eyecelerator at the 2024 American Academy of Ophthalmology (AAO ...

LENZ Therapeutics is developing LNZ100, an aceclidine-based eye drop, which stands to be the first of its kind for the treatment of presbyopia. According to the analyst, the mechanism of LNZ100 is ...

today announced presentations featuring LNZ100 at multiple upcoming ophthalmology and optometry medical conferences, including Eyecelerator at the 2024 American Academy of Ophthalmology (AAO ...

Eyecelerator at AAO 2024 presentation Title: CLARITY Phase 3 study data of LNZ100 for the treatment of presbyopia Format: Oral presentation Presenter: Marc Odrich, MD, Chief Medical Officer, LENZ ...